NEW YORK, June 3, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), Amgen, Inc. (NASDAQ: AMGN), WellPoint Inc. (NYSE: WLP) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3241-100free.
--
Biogen Idec Inc. Analyst Notes
On May 28, 2014, Biogen Idec Inc. (Biogen Idec) announced that the Company will host its 2014 Annual Shareholder Meeting on Thursday, June 12, 2014, at 9:00 a.m. ET, which will be webcast live on Biogen Idec's website. The Company stated that an archived version of the same will also be available following the meeting. The full analyst notes on Biogen Idec are available to download free of charge at:
http://www.analystsreview.com/Jun-03-2014/BIIB/report.pdf
--
UnitedHealth Group Inc. Analyst Notes
On May 28, 2014, UnitedHealthcare, one of the businesses of UnitedHealth Group Inc. (UnitedHealth Group) introduced its Multi-Choice Plan that will enable small-business owners in Rhode Island to choose from 18 different medical plan designs, each with different coverage levels, deductibles, and premiums. According to the Company, the employers will define their level of financial contribution and allow their employees to pick the plan that best addresses their unique needs. "Many small businesses want to continue offering health benefits to their employees, and with UnitedHealthcare's Multi-Choice exchange plan, they no longer need to feel limited in the benefit options they can offer to address their employees' unique needs," said Stephen Farrell, CEO, UnitedHealthcare of New England. "UnitedHealthcare will continue to develop plans to provide Rhode Island employers and their staffs with the broadest choices." The full analyst notes on UnitedHealth Group are available to download free of charge at:
http://www.analystsreview.com/Jun-03-2014/UNH/report.pdf
--
Amgen, Inc. Analyst Notes
On May 23, 2014, Amgen, Inc. (Amgen) announced that the U.S. Food and Drug Administration (FDA) has approved the first-line use of Vectibix® (panitumumab) with FOLFOX, an oxaliplatin-based chemotherapy regimen, for patients with wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC). This approval makes Vectibix® the first and only biologic to offer a significant survival benefit as a first-line treatment, in combination with FOLFOX. In addition, the Company stated that this FDA approval converts the accelerated monotherapy approval to a full approval for Vectibix®. Amgen added that the FDA has also approved the therascreen® KRAS RGQ PCR Kit developed by QIAGEN (therascreen KRAS test) as a companion diagnostic for Vectibix. "Because every patient with cancer is unique, we have made it our mission to focus on identifying treatment options for patients based on their cancer's genetic makeup," said Sean E. Harper, M.D., Executive Vice President of Research and Development, Amgen. "Approval of Vectibix in combination with FOLFOX for first-line treatment of patients with wild-type KRAS metastatic colorectal cancer is an example of the advancements that can be made through a greater understanding of distinct genetic markers associated with difficult-to-treat diseases." The full analyst notes on Amgen are available to download free of charge at:
http://www.analystsreview.com/Jun-03-2014/AMGN/report.pdf
--
WellPoint Inc. Analyst Notes
On May 29, 2014, WellPoint Inc. (WellPoint) announced that the Company will present at the Jefferies 2014 Global Health Conference on Wednesday, June 4, 2014, at 8:30 a.m. EDT, and at the Goldman Sachs 35th Annual Global Healthcare Conference on Tuesday, June 10, 2014, at 10:40 a.m. PDT (1:40 p.m. EDT). The Company stated that audio webcasts can be accessed at WellPoint's website, and its replay will also be available at the same location for two weeks after the conclusion of the events. The full analyst notes on WellPoint are available to download free of charge at:
http://www.analystsreview.com/Jun-03-2014/WLP/report.pdf
--
Mylan Inc. Analyst Notes
On May 29, 2014, Mylan Inc. (Mylan) announced that it has launched Atovaquone and Proguanil Hydrochloride Tablets in 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone® Tablets. Mylan reported that it received the final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is intended for treatment of Plasmodium Falciparum malaria and for the treatment of acute, uncomplicated P. falciparum malaria. According to IMS Health, Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg, had recorded U.S. sales of approximately $89.4 million for the 12 month period ended March 31, 2014. The full analyst notes on Mylan are available to download free of charge at:
http://www.analystsreview.com/Jun-03-2014/MYL/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
